Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.813 USD | -12.10% | -1.99% | +116.37% |
04/06 | LadRx Corporation and ImmunityBio, Inc. Mutually Agree to Terminate Aldoxorubicin License | CI |
15/05 | LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe1st Jan change | Capi. | |
---|---|---|
+116.37% | 13.93L | |
+48.80% | 5.69TCr | |
+39.98% | 4.03TCr | |
-6.93% | 3.93TCr | |
-4.42% | 2.84TCr | |
+12.02% | 2.64TCr | |
-17.89% | 1.94TCr | |
+29.69% | 1.25TCr | |
+25.19% | 1.22TCr | |
-0.15% | 1.21TCr |
- Stock Market
- Equities
- LADX Stock
- News LadRx Corporation
- Transcript : CytRx Corporation, Q3 2018 Earnings Call, Nov 02, 2018